Remeglurant

Remeglurant
Clinical data
Other names	MRZ-8456
ATC code	None;
Identifiers
	IUPAC name (6-Bromopyrazolo[1,5-a]pyrimidin-2-yl)[(1R)-1-methyl-3,4-dihydro-2(1H)-isoquinolinyl]methanone;
CAS Number	1309783-00-3;
PubChem CID	24810684;
ChemSpider	32701693;
UNII	Y7H8880HMD;
Chemical and physical data
Formula	C17H15BrN4O
Molar mass	371.238 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1c2ccccc2CCN1C(=O)c3cc4ncc(cn4n3)Br;
	InChI InChI=1S/C17H15BrN4O/c1-11-14-5-3-2-4-12(14)6-7-21(11)17(23)15-8-16-19-9-13(18)10-22(16)20-15/h2-5,8-11H,6-7H2,1H3/t11-/m1/s1; Key:TUYZYSNXXSTKQX-LLVKDONJSA-N;

Remeglurant (INN; developmental code name MRZ-8456) is a drug which acts as a selective antagonist of the mGlu₅ receptor.[1][2][3] It is under development by Merz Pharmaceuticals for the treatment of drug-induced dyskinesia but no development has been reported since at least 2016.[3]

References

World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN): Proposed INN: List 109" (PDF). WHO Drug Information. World Health Organization. 27 (2).
US 7985753, Danysz W, Dekundy A, Hechenberger M, Henrich M, Jatzke C, Nagel J, Parsons CG, Weil T, Fotins J, Gutcaits A, Kalvinsh I, Zemribo R, Kauss V, "Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators.", issued 4 August 2006, assigned to Merz Pharmaceuticals GmbH
"Remeglurant". Adis Insight. Springer Nature Switzerland AG.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.